1-2 of 2 results for subject:Reviews
Librarians' tools
- Search time
- 0.164 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Reviews
- We searched for
- subject_t:Reviews OR subject_ses:12492
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask Her Majesty's Government what discussions, if any, they have had with the (1) National Institute for Health and Care Excellence (NICE), and (2) NHS England, about the ambition of the NICE Methods Review; and whether the ambition of the review meets the targets of the Life Sciences Vision.
To ask Her Majesty's Government what discussions, if any, they have had with the (1) National Institute for Health and Care Excellence (NICE), and (2) NHS England, about the ambition of the NICE Methods Review; and whether the ambition of the review meets the targets of the Life Sciences Vision.
Officials have discussed the ambition of the methods review with the National Institute for Health and Care Excellence (NICE) and NHS England and NHS Improvement. We are supportive of NICE’s proposals, which are consistent with the expectations set out in the Voluntary Scheme for Branded Medicines Pricing and Access, agreed with industry. NICE’s review of its methods and processes will ensure it retains global leadership in the evaluation and appraisal of new medicines and technologies. As reflected in the Life Sciences Vision, this will support our ambition to promote the United Kingdom as the best place in the world to develop, trial, launch and adopt innovative new medicines.
To ask Her Majesty's Government what assessment they have made of whether the changes proposed in the National Institute for Health and Care Excellence's Methods Review will help deliver on their ambition for the UK to be a global life sciences hub.
To ask Her Majesty's Government what assessment they have made of whether the changes proposed in the National Institute for Health and Care Excellence's Methods Review will help deliver on their ambition for the UK to be a global life sciences hub.
The Department supports the proposals in the National Institute for Health and Care Excellence’s (NICE) review of its methods and processes. The proposals are consistent with the expectations for the review in the Voluntary Scheme for Branded Medicines Pricing and Access, agreed with industry. NICE’s review will ensure it retains global leadership in the evaluation and appraisal of new medicines and technologies which will promote the United Kingdom as the best place in the world to develop, trial, launch and adopt innovative new medicines, improving patient access. While it is too early to comment on the final changes to NICE’s methods and processes, NICE is reviewing the responses to its latest consultation and expects to publish the final programme manual in early 2022.